HUL has clinched the deal to buy Horlicks maker GSK's India consumer business.
Recommended ArticlesView All
This Microsoft project is enabling the digital presence of low-resource languages
Jan 30, 2023 IST7 Min(s) Read
CEOs, CXOs may see 9.1% salary hike, focus on performance-linked pay: Survey
Jan 30, 2023 IST4 Min(s) Read
Wizards of the Street | Cash is a depreciating asset and an opportunity, says Vijay Kedia
Jan 30, 2023 IST2 Min(s) Read
Prakash Javadekar — Challenging task in hand as Kerala in-charge of BJP
Jan 30, 2023 IST8 Min(s) Read
HUL will merge GSK consumer healthcare with itself and will allot 4.39 equity shares for 1 share of GSK cons healthcare in the all-equity deal.
The deal values the total business of GSK consumer at Rs 31,700 crore
HUL's parent Unilever will buy brand Horlicks from GSK plc. Brands like Boost, Viva and Maltova will be retained by the merged entity.
GSK PLC will own 5.7 percent of the merged entity post the deal. Unilever shareholding in merged entity will be 61.9 percent vs 67.2 percent prior to the merger.
The deal will be completed in one year subject to approvals. HUL will distribute GSK's OTC products for 5 years. HUL expects synergy benefits of 800-1,000 bps to margins post this deal.